Sri Lanka begins vaccine rollout for children

29 September 2021 03:51 am Views - 446

What you need to know about Covid-19 developments this week

 

A health worker inoculates a child with a dose of the Pfizer-BioNTech vaccine in Colombo on September 24, 2021 (AFP)

  • An estimated 50,000 children with comorbidities in Sri Lanka
  • Children with chronic illnesses including kidney, heart, neurological, gastrointestinal and urinary disease, as well as thalassaemia given priority
  • Recent trial from Pfizer showed favourable safety profile and robust neutralising antibody responses in children between 5 to 11 years of age
  • Vaccination of healthy children to commence once specialist recommendations are finalised

 

The Sri Lankan government last week rolled out its vaccination programme for children. Deliberated for weeks by technical committees, the programme saw the COVID-19 vaccine being administered to children between 12 to 19 years who either have comorbidities or disabilities. 


Medical experts have since encouraged parents to vaccinate children who are suffering from chronic diseases, including diabetes, kidney disease, heart disease, neurological disease, thalassaemia, gastrointestinal disease as well as diseases of the urinary tract. 


The vaccine is administered with permission of the parents and upon recommendations of the relevant specialist doctors whose care children have sought during clinical assessments and treatments. 


While the initial round of vaccination for children with special needs kicked off at the Lady Ridgeway Hospital for Children in Colombo, and hospitals in Anuradhapura and Kurunegala on Friday, September 24, the government said measures are underway to implement similar vaccination programmes in every province and district, in consultation with specialist doctors and paediatricians. 


An estimated 50,000 children in Sri Lanka suffer from comorbidities and therefore are vulnerable if the deadly virus is contracted. The vaccine identified as suitable for this group of children was the coveted Pfizer vaccine. On September 20, the vaccine maker Pfizer Inc. and BioNTech SE announced that results from a recent trial showed a favourable safety profile and robust neutralising antibody responses in children between 5 to 11 years of age, when given two-dose regimen, administered 21 days apart. 


Accordingly, Sri Lankan authorities have stated that the vaccination of healthy children between the age group of 15-19 years and the age group between 12-15, will commence as soon as specialist recommendations have been finalised.


However, medical experts in the past few weeks have warned of a worrisome anti-vaccination campaign that is brewing in Sri Lanka, where parents and youths who have been offered the vaccine are hesitating or refusing to get the jab. During a recent media briefing organised by the Department of Government Information, Professor of Community Health at the Medical Faculty of the University of Colombo, M. Weerasinghe said this. 


Prof. Weerasinghe suggested that there were strong misinformation camps that the immunity offered by different vaccines differed. All vaccines recommended by the WHO have good capacity of immunisation, he said, adding that the Pfizer vaccine has been recommended for children between 12 to 18 years of age. Countries such as the United States, Australia, Germany, Switzerland, Norway and the United Kingdom have already vaccinated children of particular age groups, therefore Sri Lankan parents have no cause for concern, the medical experts stressed. 
Community Health Specialist and Director of Family Health Bureau Dr. Chithramali de Silva meanwhile said that Sri Lanka has a strong history of successful immunisation campaigns which has led to the country recording lowest child mortality rates in South Asia. “Vaccination of children began in 1961 and it was later carried out island-wide by 1978. Sri Lanka has been successful in administering relevant and necessary vaccines to children at the appropriate time,” she said. Both doctors stressed that vaccination has been key in reducing mortality and spread of major contagious disease outbreaks in Sri Lanka, stressing that public should maintain faith in these medical interventions.

COVID-19 Global Developments

Only a handful of countries or territories have been left with no active Covid-19 cases, as they managed to keep the deadly global pandemic at bay. From the United Nations to Italy and India, second or third waves of the illness have worsened conditions than when the pandemic initially hit in early 2020. In Sri Lanka where lockdowns and travel restrictions have eased, its citizens are benefitting from an accelerated vaccination rollout by the government.  
Since the outbreak of the disease in China in 2019, health authorities in over 200 countries reported an approximate 187.8 million Covid-19 cases and 4 million deaths. Countries across Asia, Americas and Africa are seeing a resurgence in COVID-19 cases, forcing them to bring back or extend stringent lockdowns and hampering drives to vaccinate their population. Here’s a look at the latest global developments of the Coronavirus.

EUROPE 

ASIA-PACIFIC 

AMERICAS 

MIDDLE EAST AND AFRICA 

ECONOMIC IMPACT 

MEDICAL DEVELOPMENTS 

WHO warns individuals against mixing and matching COVID vaccines

The World Health Organisation’s chief scientist has advised individuals against mixing and matching COVID-19 vaccines from different manufacturers, saying such decisions should be left to public health authorities.
“It’s a little bit of a dangerous trend here,” Soumya Swaminathan told an online briefing on Monday after a question about booster shots. “It will be a chaotic situation in countries if citizens start deciding when and who will be taking a second, a third and a fourth dose.” Swaminathan had called mixing a “data-free zone” but later clarified her remarks in an overnight tweet.


“Individuals should not decide for themselves, public health agencies can, based on available data,” she said in the tweet. “Data from mix and match studies of different vaccines are awaited - immunogenicity and safety both need to be evaluated.” The WHO’s Strategic Advisory Group of Experts on vaccines said in June the Pfizer Inc vaccine could be used as a second dose after an initial dose of AstraZeneca, if the latter is not available.
A clinical trial led by the University of Oxford in the UK is ongoing to investigate mixing the regimen of AstraZeneca and Pfizer vaccines. The trial was recently expanded to include the Moderna Inc and Novovax Inc vaccines.

(Reuters)